Novartis to buy siRNA developer DTx Pharma for up to $1B

No­var­tis will con­tin­ue to add siR­NA ca­pa­bil­i­ties to its tool belt in a deal worth up to $1 bil­lion.

The Swiss phar­ma ac­quired DTx Phar­ma, a San Diego-based biotech with a siR­NA ther­a­py that it wants to start test­ing in pa­tients with Char­cot-Marie-Tooth dis­ease Type 1A (CMT1A), a neu­ro­mus­cu­lar dis­ease that can cause loss of mus­cle func­tion.

There are about 150,000 pa­tients with CMT1A in the US and Eu­rope.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN